TY - JOUR
T1 - Bi-specific and Tri-specific NK Cell Engagers
T2 - The New Avenue of Targeted NK Cell Immunotherapy
AU - Phung, Shee Kwan
AU - Miller, Jeffrey S.
AU - Felices, Martin
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2021/9
Y1 - 2021/9
N2 - Natural killer (NK) cell-mediated cancer immunotherapy has grown significantly over the past two decades. More recently, multi-specific engagers have been developed as cancer therapeutics to effectively arm endogenous NK cells to more potently induce specific cytolytic responses against tumor targets. This review explores the bi- and tri-specific NK/tumor engagers that are emerging as a new generation of immunotherapeutics. These molecules vary in configuration, but they typically have small molecular weights and domains that engage specific tumor antigens and NK cell-activating receptors such as CD16, NKp30, NKp46, and NKG2D. They have demonstrated compelling potential in boosting NK cell cytotoxicity against specific tumor targets. This highly adaptable off-the-shelf platform, which in some formats also integrates cytokines, is poised to revolutionize targeted NK cell immunotherapy, either as a monotherapy or in combination with other effective anti-cancer therapies.
AB - Natural killer (NK) cell-mediated cancer immunotherapy has grown significantly over the past two decades. More recently, multi-specific engagers have been developed as cancer therapeutics to effectively arm endogenous NK cells to more potently induce specific cytolytic responses against tumor targets. This review explores the bi- and tri-specific NK/tumor engagers that are emerging as a new generation of immunotherapeutics. These molecules vary in configuration, but they typically have small molecular weights and domains that engage specific tumor antigens and NK cell-activating receptors such as CD16, NKp30, NKp46, and NKG2D. They have demonstrated compelling potential in boosting NK cell cytotoxicity against specific tumor targets. This highly adaptable off-the-shelf platform, which in some formats also integrates cytokines, is poised to revolutionize targeted NK cell immunotherapy, either as a monotherapy or in combination with other effective anti-cancer therapies.
UR - http://www.scopus.com/inward/record.url?scp=85111582295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111582295&partnerID=8YFLogxK
U2 - 10.1007/s40291-021-00550-6
DO - 10.1007/s40291-021-00550-6
M3 - Review article
C2 - 34327614
AN - SCOPUS:85111582295
SN - 1177-1062
VL - 25
SP - 577
EP - 592
JO - Molecular Diagnosis and Therapy
JF - Molecular Diagnosis and Therapy
IS - 5
ER -